|
|
Article: TKT Announces Expiration of Both Hart-Scott-Rodino Waiting Period and SEC Review Period of Preliminary Proxy Statement.
- Article from:
- PR Newswire
- Article date:
- June 13, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass., June 13 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. today announced that the 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired on June 10, 2005 with respect to the proposed acquisition of the company by Shire Pharmaceuticals Group plc. In addition, TKT also announced that the SEC's ten-day period for reviewing the company's preliminary proxy statement relating to the stockholder meeting to approve the proposed acquisition by Shire has expired. The company has not yet set a meeting date for the stockholder meeting to approve the acquisition, but has set a record date for the meeting of ...